Valuation : Ionis Pharmaceuticals, Inc.

Market Cap 10.15B 8.74B 8.2B 7.48B 14.1B 970B 14.14B 97.25B 37.94B 489B 38.09B 37.26B 1,623B P/E 2026 *
-16.8x
P/E 2027 * -32.3x
Enterprise Value 10.04B 8.65B 8.11B 7.41B 13.95B 960B 14B 96.26B 37.56B 485B 37.7B 36.88B 1,607B EV / Sales 2026 *
11x
EV / Sales 2027 * 7.28x
Free-Float
99.05%
Yield 2026 *
-
Yield 2027 * -
1 day-2.21%
1 week+2.19%
Current month+17.93%
1 month+12.97%
3 months-20.20%
6 months-24.77%
Current year-22.83%
1 week 59.7
Extreme 59.7
64.19
1 month 51.28
Extreme 51.28
64.19
Current year 50
Extreme 50.005
86.74
1 year 49.13
Extreme 49.13
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 01/07/2012
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/05/2000
Director TitleAgeSince
Director/Board Member 64 13/12/2005
Director/Board Member 73 01/05/2002
Director/Board Member 64 25/03/2019
Date Insider Type Main position Quantity % Market Cap.
31/07/26 Buy

Director

5,000 0.0030%
15/07/26 Free

Director

3,399 0.0021%
15/07/26 Free

Director

3,399 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
-2.21%+2.19%+43.19%+48.68% 10.15B
-0.78%-1.42%+2.96%+21.65% 50.47B
-6.00%-0.75%+447.48%+535.14% 44.56B
-0.24%+0.74%+37.18%+16.26% 43.08B
-1.55%-2.07%+19.83%+71.70% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.79%-3.24%+26.32%+125.06% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.63%+27.62% 14.58B
-1.66%-1.25%+78.49%+42.97% 13.92B
Average -1.60%-0.73%+76.28%+104.15% 28.47B
Weighted average by Cap. -1.72%-0.94%+94.27%+126.00%

Financials

2026 *2027 *
Net sales 913M 787M 738M 674M 1.27B 87.3B 1.27B 8.76B 3.42B 44.07B 3.43B 3.35B 146B 1.4B 1.21B 1.13B 1.03B 1.95B 134B 1.95B 13.44B 5.24B 67.64B 5.26B 5.15B 224B
Net income -602M -519M -487M -444M -837M -57.58B -840M -5.77B -2.25B -29.06B -2.26B -2.21B -96.37B -326M -281M -263M -240M -453M -31.14B -454M -3.12B -1.22B -15.72B -1.22B -1.2B -52.13B
Net Debt -103M -88.72M -83.19M -75.94M -143M -9.84B -144M -987M -385M -4.97B -387M -378M -16.47B 57.45M 49.51M 46.42M 42.37M 79.83M 5.49B 80.08M 551M 215M 2.77B 216M 211M 9.19B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,480
Date Price Change Volume
28/08/26 $61.05 -2.21% 1,850,852
27/08/26 $62.43 -1.47% 1,625,581
26/08/26 $63.36 -0.33% 2,152,847
25/08/26 $63.57 +2.47% 2,435,239
24/08/26 $62.04 +3.85% 2,207,101
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
61.05USD
Average target price
88.00USD
Spread / Average Target
+44.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock